New Developments in Diagnosis, Prognosis, and Assessment of Response in Multiple Myeloma.
Over the past few years, the management of multiple myeloma has changed. We have new guidelines regarding how to set the diagnosis, when to initiate therapy, and how to monitor treatment response. In 2014, the updated International Myeloma Working Group (IMWG) diagnostic criteria changed the definition of multiple myeloma from being a disease defined by symptoms to a disease defined by biomarkers. Today, modern combination therapies have reported up to 60% to 80% of patients reaching a complete response. As a logical and necessary step forward, investigators have explored strategies to detect minimal residual disease (MRD) and its correlation with clinical outcomes. Recent meta-analysis data show that MRD negativity is associated with longer progression-free survival and overall survival. In 2016, the updated IMWG response criteria include MRD as the deepest level of treatment response in multiple myeloma. Simultaneously, we are still quite behind in our understanding of the heterogeneous biology of multiple myeloma and its implications for therapy. Emerging DNA sequencing data show that newly diagnosed multiple myeloma patients have a broad range of mutations, which are distributed unevenly in multiple parallel subclones already present at diagnosis. To move beyond the ill-defined category of "high-risk multiple myeloma," which confers to approximately 25% of all newly diagnosed patients, prospective studies are needed to dissect tumor biology and define multiple myeloma subtypes, and, based on biology, seek to define rational therapies for individual subtypes. This article discusses novel insights and gives perspectives on diagnosis and MRD monitoring and future directions for prognosis and clinical management of multiple myeloma. Clin Cancer Res; 22(22); 5428-33. ©2016 AACR SEE ALL ARTICLES IN THIS CCR FOCUS SECTION, "MULTIPLE MYELOMA MULTIPLYING THERAPIES".
Myeloma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York. landgrec@mskcc.org.
Ola
O
Landgren
Division of Hematology, Mayo Clinic, Rochester, Minnesota.
S Vincent
SV
Rajkumar
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D018572:Disease-Free Survival; D006801:Humans; D015201:Meta-Analysis as Topic; D009101:Multiple Myeloma / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology*; D009154:Mutation / Q000187:drug effects; D018365:Neoplasm, Residual / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology; D011379:Prognosis; D011446:Prospective Studies; D012074:Remission Induction / Q000379:methods